IMAGE: Lymph node and osseous metastatic, castration-resistant, and chemotherapy-naive prostate cancer (status post androgen-deprivation therapy using LHRH analogs and Bicalutamide) in a 62-year-old patient demonstrated no evidence of disease on Ga-68… view more
Credit: HR Kulkarni et al., THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany
PHILADELPHIA – Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates for the first time the benefit of providing earlier lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy to patients with metastatic prostate cancer. Until now, this therapy has only been used in patients with end-stage disease.
The study included 224 patients with metastatic prostate cancer, who were restaged following diagnosis with gallium-68 (68Ga)-PSMA positron emission tomography/computed tomography (PET/CT)–the diagnostic partner of 177Lu-PSMA radioligand therapy (PRLT); the two form a theranostic nuclear medicine pairing. Theranostics refers to the combination of a predictive biomarker, in this case PSMA, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-identified cancer cells. The cancer cells are destroyed, while healthy cells are unharmed–minimizing side effects and improving quality of life for patients.
Article originally posted at